Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT01657461

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01657461
Other papers using this trial's data
  • Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) Stroke, 2017-02 DOI, PubMed 28028150, PMC5461963 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) Stroke, 2017-06 DOI, PubMed 28465460
  • Predictive Value of RAPID Assessed Perfusion Thresholds on Final Infarct Volume in SWIFT PRIME (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment) Stroke, 2017-04 DOI, PubMed 28283606
  • Relationships Between Imaging Assessments and Outcomes in Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke Stroke, 2015-10 DOI, PubMed 26316344
  • Relative cerebral blood volume is associated with collateral status and infarct growth in stroke patients in SWIFT PRIME Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2018-10 DOI, PubMed 29135347, PMC6168913 PubMed links an erratum for this paper. Erratum: PMID 29519174 Not in the PMC Open Access subset.
  • Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke The New England journal of medicine, 2015-06-11 DOI, PubMed 25882376

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01657461. Randomized; no masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2015-01 (actual). Results posted on 2017-05-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
Acronym
SWIFT PRIME
Condition
Acute Ischemic Stroke
Intervention (Drug)
Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
Intervention (Device)
Solitaire revascularization device
Lead sponsor
Medtronic Neurovascular Clinical Affairs (class: industry)

Record details

Record id
cardio:ct-nct01657461
Content hash
0036b2d9265f6f0ac080b4e41c2ced2939a7bca43f1054e12c0d10a9c719e6fd